Pharmanovia acquires CNS portfolio from Sanofi

18 September 2023

UK-based lifecycle management and pharma manufacturing company Pharmanovia today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from French pharma major Sanofi (Euronext: SAN).

Pharmanovia says this marks a significant milestone for the company, as its brand portfolio now covers four critical areas of unmet needs related to CNS disorders: psycholeptic, anxiolytic, anti-epileptic, and anti-psychotic medications. No financial terms of the transaction were revealed.

One of the drugs is Frisium (clobazam), which is from a class of medicines called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients. Clobazam is also marketed under the trade names Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium. Frisium may also be used as adjunctive therapy in epilepsy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK